ABSTRACT
This study was to investigate the relationship of dose-effect and time-effect of Alginate-Polylysine-Alginate (APA) microencapsulated bovine chromaffin cells on the treatment of pain model rats. Using a rat model of painful peripheral neuropathy, the antinociceptive effects of APA microencapsulated bovine cells transplanted into the subarachnoid space was evaluated by cold allodynia test and hot hyperalgesia test. Compared with control group, the withdrawal difference with cell number 50 thousands groups, 100 thousands groups and 200 thousands groups was reduced (P < 0.05), and the difference decreased with the cells increases, indicating a significant analgesic effect. There was no significant difference between 400 thousands groups and 200 thousands groups. This analgesic effect maintained longer than 12 weeks. There was a positive correlation between the analgesic effect and the quantity of APA microencapsulated bovine chromaffin cells which were transplanted to treat pain model rats, and the effective antinociception remained longer than 12 weeks.
Subject(s)
Alginates/administration & dosage , Analgesia/methods , Chromaffin Cells/transplantation , Implants, Experimental , Pain Management/methods , Polylysine/analogs & derivatives , Alginates/pharmacology , Animals , Cattle , Dose-Response Relationship, Drug , Drug Compounding , Polylysine/administration & dosage , Polylysine/pharmacology , Rats , Sciatica/therapyABSTRACT
OBJECTIVE: To study the therapeutic effect and mechanism of Dachengqi granule (DCQG) on some digestive motility disturbed diseases. METHODS: Gastroduodenojejunal manometry, electrogastrography (EGG), RIA of motilin and orocecal transit time test were applied to directly observe the effect of DCQG on human gastrointestinal motility. RESULTS: DCQG could significantly improve the postoperational EGG disorder, elevate the amplitude and time of migrating motor complex (MMC) phase III, prevent gastrointestinal reversed peristalsis, increase the blood level of motilin, decrease the orocecal transit time, and promote the recovery of gastrointestinal motility. CONCLUSION: DCQG is an effective digestive kinetic agent, which could be medicated conveniently in treating digestive motility disturbed diseases.
